Who’s Leading the Biosimilars Race?

US biopharma giants, Pfizer and Amgen, along with South Korea’s Celltrion are emerging as frontrunners in the biosimilars race


Biochemical test tubes in lines at a laboratoryWhile Sandoz/Novartis can claim victory with the first FDA biosimilar approval of Zarxio in March, it’s Pfizer, Amgen and Celltrion that have the volume of biosimilars in the pipeline

Amgen, Pfizer and Novartis are wisely playing both sides of field – capitalizing on the new biosimilars market, while continuing to develop original biologics. And with such a tightly-run race, it will be interesting to see who comes out on top by year’s end.

Read More